1. Home
  2. RCL vs REGN Comparison

RCL vs REGN Comparison

Compare RCL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCL
  • REGN
  • Stock Information
  • Founded
  • RCL 1968
  • REGN 1988
  • Country
  • RCL United States
  • REGN United States
  • Employees
  • RCL N/A
  • REGN N/A
  • Industry
  • RCL Marine Transportation
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RCL Consumer Discretionary
  • REGN Health Care
  • Exchange
  • RCL Nasdaq
  • REGN Nasdaq
  • Market Cap
  • RCL 63.0B
  • REGN 56.7B
  • IPO Year
  • RCL N/A
  • REGN 1991
  • Fundamental
  • Price
  • RCL $350.92
  • REGN $559.53
  • Analyst Decision
  • RCL Strong Buy
  • REGN Buy
  • Analyst Count
  • RCL 19
  • REGN 21
  • Target Price
  • RCL $316.63
  • REGN $823.86
  • AVG Volume (30 Days)
  • RCL 2.7M
  • REGN 921.6K
  • Earning Date
  • RCL 07-29-2025
  • REGN 08-01-2025
  • Dividend Yield
  • RCL 0.86%
  • REGN 0.62%
  • EPS Growth
  • RCL 60.94
  • REGN 16.49
  • EPS
  • RCL 12.30
  • REGN 39.43
  • Revenue
  • RCL $16,756,000,000.00
  • REGN $14,085,700,000.00
  • Revenue This Year
  • RCL $10.52
  • REGN N/A
  • Revenue Next Year
  • RCL $9.59
  • REGN $6.77
  • P/E Ratio
  • RCL $28.41
  • REGN $14.32
  • Revenue Growth
  • RCL 13.66
  • REGN 7.52
  • 52 Week Low
  • RCL $130.08
  • REGN $476.49
  • 52 Week High
  • RCL $355.91
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • RCL 74.73
  • REGN 54.83
  • Support Level
  • RCL $348.87
  • REGN $541.50
  • Resistance Level
  • RCL $355.91
  • REGN $577.73
  • Average True Range (ATR)
  • RCL 6.94
  • REGN 14.70
  • MACD
  • RCL -1.38
  • REGN 1.58
  • Stochastic Oscillator
  • RCL 83.27
  • REGN 53.10

About RCL Royal Caribbean Cruises Ltd.

Royal Caribbean is the world's second-largest cruise company, operating 66 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021 and plans to launch its new Celebrity River Cruise brand in 2027.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: